Challenges in the Metabolomics-Based Biomarker Validation Pipeline

Shenghan Li,Nikita Looby,Vinod Chandran,Vathany Kulasingam
DOI: https://doi.org/10.3390/metabo14040200
IF: 4.1
2024-04-03
Metabolites
Abstract:As end-products of the intersection between the genome and environmental influences, metabolites represent a promising approach to the discovery of novel biomarkers for diseases. However, many potential biomarker candidates identified by metabolomics studies fail to progress beyond analytical validation for routine implementation in clinics. Awareness of the challenges present can facilitate the development and advancement of innovative strategies that allow improved and more efficient applications of metabolite-based markers in clinical settings. This minireview provides a comprehensive summary of the pre-analytical factors, required analytical validation studies, and kit development challenges that must be resolved before the successful translation of novel metabolite biomarkers originating from research. We discuss the necessity for strict protocols for sample collection, storage, and the regulatory requirements to be fulfilled for a bioanalytical method to be considered as analytically validated. We focus especially on the blood as a biological matrix and liquid chromatography coupled with tandem mass spectrometry as the analytical platform for biomarker validation. Furthermore, we examine the challenges of developing a commercially viable metabolomics kit for distribution. To bridge the gap between the research lab and clinical implementation and utility of relevant metabolites, the understanding of the translational challenges for a biomarker panel is crucial for more efficient development of metabolomics-based precision medicine.
biochemistry & molecular biology
What problem does this paper attempt to address?
### Problems the paper attempts to solve This paper aims to explore the challenges faced in the biomarker validation process based on metabolomics. Although metabolomics has great potential in discovering new disease biomarkers, many potential biomarker candidates have not been widely used in clinical practice after passing analytical validation. The paper emphasizes the following challenges: 1. **Pre - analytical factors**: - **Patient selection**: The metabolome of patients is affected by genetic and environmental factors. Therefore, strict control of patient selection criteria is required to reduce the impact of confounding factors on the results. - **Sample collection and storage**: The way of sample collection and storage is crucial to the accuracy of the results. For example, the choice of anticoagulants, sampling time (taking into account circadian rhythms and dietary status), standardized operating procedures (SOPs) for sample processing, and storage temperature all affect the stability of the metabolome. 2. **Analytical validation**: - **Analytical validation parameters**: According to the latest guidelines of the International Council for Harmonisation (ICH), multiple parameters need to be validated, including selectivity, specificity, calibration curves, accuracy, precision, stability, and dilution linearity. The validation of these parameters ensures the reliability and accuracy of the method. - **Stability requirements**: The stability of metabolites under different conditions, such as freeze - thaw cycles, short - term stability at room temperature, and long - term stability in freezing, needs to be evaluated. 3. **Kit development**: - **Commercial feasibility**: Developing a commercially viable metabolomics kit faces multiple challenges, including compatibility with instruments, regulatory requirements of manufacturers and distributors, user - friendliness, cost - effectiveness, and analysis time. By solving these challenges, the transformation efficiency of metabolomics biomarkers from research laboratories to clinical applications can be improved, thus promoting the development of precision medicine.